Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression

Breast cancer is common worldwide, and the estrogen receptor-positive subtype accounts for approximately 70% of breast cancer in women. Tamoxifen and fulvestrant are drugs currently used for endocrinal therapy. Breast cancer exhibiting endocrine resistance can undergo metastasis and lead to the deat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yueh-Te, Lin, Joseph, Liu, Yi-En, Hsu, Kai-Wen, Hsieh, Chang-Chi, Chen, Dar-Ren, Wu, Han-Tsang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665409/
https://www.ncbi.nlm.nih.gov/pubmed/34890965
http://dx.doi.org/10.1016/j.tranon.2021.101302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665409/
https://www.ncbi.nlm.nih.gov/pubmed/34890965
http://dx.doi.org/10.1016/j.tranon.2021.101302

Ejemplares similares